Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel combination of ...

Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

PDAC, an aggressive and often difficult-to-diagnose cancer, frequently spreads before detection. The study, published in the ...

Merger Completion: On August 15, 2024, Silexion completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq under the ticker “SLXN.” This strategic ...

A novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with ...